InsiderTrades.com logo
Matthew Angel net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Matthew Angel Biography and Net Worth

President and Chief Executive Officer of Tempest Therapeutics

Matt Angel, Ph.D. has served as Tempest Therapeutic Inc.’s Chief Executive Officer, President and as a member of our Board since February 2026. Dr. Angel has also served as Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors of Factor Bioscience Inc. since 2011. From January 2023 to December 2023, Dr. Angel served as President and Chief Executive Officer and as a director of Ernexa Therapeutics Inc. (f/k/a Eterna Therapeutics Inc.). From May 2022 to December 2022, Dr. Angel served as Interim President, Chief Executive Officer and as a director of Ernexa Therapeutics Inc. In 2020, Dr. Angel co-founded Exacis Biotherapeutics Inc. (“Exacis”) and served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis from 2020 until the sale of Exacis in May 2023. Dr. Angel also co-founded and served as the Chief Science Officer, Secretary and as a director of Novellus, Inc., from 2014 until the sale of Novellus in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.

What is Matthew Angel's net worth?

The estimated net worth of Matthew Angel is at least $181.48 thousand as of March 24th, 2026. Dr. Angel owns 231,482 shares of Tempest Therapeutics stock worth more than $181,482 as of October 6th. This net worth evaluation does not reflect any other investments that Dr. Angel may own. Learn More about Matthew Angel's net worth.

How do I contact Matthew Angel?

The corporate mailing address for Dr. Angel and other Tempest Therapeutics executives is 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, 94005. Tempest Therapeutics can also be reached via phone at 415-798-8589 and via email at [email protected]. Learn More on Matthew Angel's contact information.

Has Matthew Angel been buying or selling shares of Tempest Therapeutics?

Matthew Angel has not been actively trading shares of Tempest Therapeutics over the course of the past ninety days. Most recently, on Tuesday, March 24th, Matthew Angel bought 231,482 shares of Tempest Therapeutics stock. The stock was acquired at an average cost of $2.16 per share, with a total value of $500,001.12. Following the completion of the transaction, the chief executive officer now directly owns 231,482 shares of the company's stock, valued at $500,001.12. Learn More on Matthew Angel's trading history.

Who are Tempest Therapeutics' active insiders?

Tempest Therapeutics' insider roster includes Matthew Angel (President and Chief Executive Officer), and Thomas Dubensky (President). Learn More on Tempest Therapeutics' active insiders.

Are insiders buying or selling shares of Tempest Therapeutics?

In the last year, Tempest Therapeutics insiders bought shares 1 times. They purchased a total of 231,482 shares worth more than $500,001.12. The most recent insider tranaction occured on March, 24th when CEO Matthew Angel bought 231,482 shares worth more than $500,001.12. Insiders at Tempest Therapeutics own 36.2% of the company. Learn More about insider trades at Tempest Therapeutics.

Information on this page was last updated on 3/24/2026.

Matthew Angel Insider Trading History at Tempest Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/24/2026Buy231,482$2.16$500,001.12231,482View SEC Filing Icon  
See Full Table

Matthew Angel Buying and Selling Activity at Tempest Therapeutics

This chart shows Matthew Angel's buying and selling at Tempest Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tempest Therapeutics Company Overview

Tempest Therapeutics logo
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Read More

Today's Range

Now: $0.78
Low: $0.77
High: $0.80

50 Day Range

MA: $0.96
Low: $0.76
High: $1.21

2 Week Range

Now: $0.78
Low: $0.74
High: $12.23

Volume

191,317 shs

Average Volume

980,117 shs

Market Capitalization

$13.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A